Biotechnology · Nasdaq
ONCBeOne Medicines Ltd.
- Last close
- $416.54 +0.1%
- 52-week range
- $253.95 to $424.73
- Market cap
- $619B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Revenue
$5.34B
+40% vs FY24
Net income
$287M
+144% vs FY24
Free cash flow
$942M
+249% vs FY24
Net cash
$3.52B
Cash $4.55B, debt $1.03B
Stock price
Valuation vs its own 10 years
Below its 10-year median on 1 multiple
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
P/E, trailing
689x
n/a: Not enough history
Price / sales
93.6x
62.7x48,109x
23rd percentile, below its median of 222x
EV / EBITDA
452x
n/a: Not enough history
Price / free cash flow
427x
n/a: Not enough history
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 689x
- Earnings yield
- 0.1%
- Price / sales
- 93.6x
- Price / book
- 106x
- Price / operating cash flow
- 389x
- EV / EBITDA
- 452x
- EV / sales
- 92.9x
- Free cash flow yield
- 0.2%
Profitability
- Gross margin
- 89.4%
- Operating margin
- 17.8%
- Net margin
- 13.9%
- Return on equity
- 15.7%
- Return on capital
- 13.6%
Growth per year
- Revenue, 3 years
- +55.7%
- Revenue, 5 years
- +76.8%
- Revenue, 9 years
- +158%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $5.78B
- Total debt
- $1.20B
- Net cash
- $4.58B
- Debt / equity
- 0.21x
- Current ratio
- 3.55x
Shares and dividend
- Shares outstanding
- 1.48B
- Share count, 5 years
- +35.9%
- Beta, 1 year
- 0.69
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Revenue and net incomeLatest quarter $1.89B
RevenueNet income
Gross profitLatest quarter $1.67B
EBITDALatest quarter $480M
Margins89 / 22 / 20%
GrossOperatingNet
Earnings per shareLatest quarter $0.25
Cash flowLatest quarter $509M
OperatingCapexFree
Cash vs debtLatest quarter $5.78B
Cash and investmentsTotal debt
P/E historyNow 689x
P/E
P/S historyNow 93.6x
P/S, median 222x dashed
Revenue and net incomeFY25 $5.34B
RevenueNet income
Gross profitFY25 $4.67B
EBITDAFY25 $589M
Margins87 / 8 / 5%
GrossOperatingNet
Earnings per shareFY25 $0.19
Cash flowFY25 $1.13B
OperatingCapexFree
Cash vs debtFY25 $4.55B
Cash and investmentsTotal debt
P/S historyNow 93.6x
P/S, median 222x dashed
Where the revenue comes from
Collaboration went from 11% to 1% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
FY22
$1.42B
FY23
$2.46B
FY24
$3.81B
FY25
$5.34B
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Product | $5.28B | 98.9% | +40% |
| Collaboration | $61.0M | 1.1% | +99% |
Biotechnology peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $619B | +33% | 17.8% | 689x | 93.6x | Not enough history |
| ABBV AbbVie Inc. | $521B | +11% | 32.2% | 50.8x | 7.9x | 72nd percentile |
| AMGN Amgen Inc | $252B | +8% | 32.4% | 27.0x | 6.5x | 78th percentile |
| GILD Gilead Sciences, Inc. | $208B | +7% | -7.6% | No earnings | 6.7x | No earnings |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137B | +10% | 33.2% | 34.7x | 10.5x | 71st percentile |
| MRNA Moderna, Inc. | $90.4B | +13% | -116% | No earnings | 35.8x | No earnings |
The company
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- Basel
- Fiscal year ends
- December
Around the numbers
What the rest of EdgeStacker knows about ONC.